Company / Gross Profit
Organon & Co. Gross Profit History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$3.3B
FY2025
5-year range
$3.3B / $3.9B
FY2022-FY2025
Trend
-10.8%
vs FY2024
Sector context
#5 of 29
Health Care
What the data says
Organon & Co.'s gross profit of $3.3B is higher than 83% of companies in the Health Care sector (FY2025). Gross Profit has declined for 3 consecutive years, from $3.9B in FY2022 to $3.3B in FY2025.
Based on SEC 10-K filings.
$3.3B in FY2025 with a 3-year CAGR of -5.1%. Top quartile in the Health Care sector.
Declined from $3.7B to $3.3B over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- -5.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 17% in Health CareTop 17% of 29This company $3.3B Sector average $3.5B
▼
-4.3% below sector average
Key checks
Key Insights
- Organon & Co.'s gross profit has declined for 3 consecutive years.
- 3-year CAGR of -5.1%, indicating a declining trend.
- In FY2025, gross profit decreased 10.8% year-over-year.
- Ranks #5 out of 29 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.3B | -10.8% |
| FY2024 | $3.7B | -0.9% |
| FY2023 | $3.7B | -3.4% |
| FY2022 | $3.9B | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026